These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 24852916)

  • 1. Usefulness of hyponatremia as a predictor for adverse events in patients with heart failure receiving cardiac resynchronization therapy.
    Sharma AK; Vegh EM; Kandala J; Orencole M; Januszkiewicz L; Bose A; Miller A; Parks KA; Heist EK; Singh JP
    Am J Cardiol; 2014 Jul; 114(1):83-7. PubMed ID: 24852916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of hypothyroidism with adverse events in patients with heart failure receiving cardiac resynchronization therapy.
    Sharma AK; Vegh E; Orencole M; Miller A; Blendea D; Moore S; Lewis GD; Singh JP; Parks KA; Heist EK
    Am J Cardiol; 2015 May; 115(9):1249-53. PubMed ID: 25743211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study.
    Hsu JC; Solomon SD; Bourgoun M; McNitt S; Goldenberg I; Klein H; Moss AJ; Foster E;
    J Am Coll Cardiol; 2012 Jun; 59(25):2366-73. PubMed ID: 22698490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyponatremia as a predictor for worsening heart failure in patients receiving cardiac resynchronization therapy.
    Arao K; Fujiwara T; Sakakura K; Wada H; Sugawara Y; Suga C; Ako J; Ishikawa SE; Momomura S
    Circ J; 2013; 77(1):116-22. PubMed ID: 23018767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implication of baseline PR interval in cardiac resynchronization therapy recipients.
    Januszkiewicz Ł; Vegh E; Borgquist R; Bose A; Sharma A; Orencole M; Mela T; Singh JP; Parks KA
    Heart Rhythm; 2015 Nov; 12(11):2256-62. PubMed ID: 26066291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
    Ruwald MH; Ruwald AC; Jons C; Alexis J; McNitt S; Zareba W; Moss AJ
    J Am Coll Cardiol; 2013 Apr; 61(14):1518-26. PubMed ID: 23500269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Association of serum albumin level and clinical outcomes among heart failure patients receiving cardiac resynchronization therapy].
    Yang SW; Liu ZM; Mi JR; Liu SY; Ding LG; Chen KP; Hua W; Zhang S
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):204-208. PubMed ID: 28316176
    [No Abstract]   [Full Text] [Related]  

  • 8. Device-measured physical activity versus six-minute walk test as a predictor of reverse remodeling and outcome after cardiac resynchronization therapy for heart failure.
    Vegh EM; Kandala J; Orencole M; Upadhyay GA; Sharma A; Miller A; Merkely B; Parks KA; Singh JP
    Am J Cardiol; 2014 May; 113(9):1523-8. PubMed ID: 24641966
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-capillary pulmonary hypertension and right ventricular dilation predict clinical outcome in cardiac resynchronization therapy.
    Chatterjee NA; Upadhyay GA; Singal G; Parks KA; Dec GW; Singh JP; Lewis GD
    JACC Heart Fail; 2014 Jun; 2(3):230-7. PubMed ID: 24952689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of weight loss on clinical outcomes in patients implanted with a cardiac resynchronization therapy device-A MADIT-CRT substudy.
    Aktas MK; Zareba W; Huang DT; McNitt S; Polonsky S; Chen L; Stockburger M; Merkely B; Moss AJ; Kutyifa V
    J Card Fail; 2014 Mar; 20(3):183-9. PubMed ID: 24361804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial.
    Gheorghiade M; Rossi JS; Cotts W; Shin DD; Hellkamp AS; Piña IL; Fonarow GC; DeMarco T; Pauly DF; Rogers J; DiSalvo TG; Butler J; Hare JM; Francis GS; Stough WG; O'Connor CM
    Arch Intern Med; 2007 Oct; 167(18):1998-2005. PubMed ID: 17923601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma galectin-3 and heart failure outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).
    Stolen CM; Adourian A; Meyer TE; Stein KM; Solomon SD
    J Card Fail; 2014 Nov; 20(11):793-9. PubMed ID: 25106783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of dosing of the renin-angiotensin system inhibitors after cardiac resynchronization therapy to long-term prognosis.
    Mantziari L; Guha K; Khalique Z; McDonagh T; Sharma R
    Am J Cardiol; 2012 Jun; 109(11):1619-25. PubMed ID: 22465318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of the risk of recurring heart failure events with cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy).
    Goldenberg I; Hall WJ; Beck CA; Moss AJ; Barsheshet A; McNitt S; Polonsky S; Brown MW; Zareba W
    J Am Coll Cardiol; 2011 Aug; 58(7):729-37. PubMed ID: 21816309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy.
    Trucco E; Tolosana JM; Castel MÁ; Batlle M; Borràs R; Sitges M; Guash E; Matas M; Arbelo E; Berruezo A; Brugada J; Mont L
    Europace; 2016 Feb; 18(2):232-7. PubMed ID: 25883077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT).
    Martin DT; McNitt S; Nesto RW; Rutter MK; Moss AJ
    Circ Heart Fail; 2011 May; 4(3):332-8. PubMed ID: 21350054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure.
    Conraads VM; Spruit MA; Braunschweig F; Cowie MR; Tavazzi L; Borggrefe M; Hill MR; Jacobs S; Gerritse B; van Veldhuisen DJ
    Circ Heart Fail; 2014 Mar; 7(2):279-87. PubMed ID: 24519908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure.
    Brenyo A; Barsheshet A; Rao M; Huang DT; Zareba W; McNitt S; Hall WJ; Peterson DR; Solomon SD; Moss AJ; Goldenberg I
    Circ Heart Fail; 2013 Sep; 6(5):998-1004. PubMed ID: 23801020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of electrocardiographic measurements before and after cardiac resynchronization device implantation in patients with heart failure due to ischemic or nonischemic cardiomyopathy.
    Iler MA; Hu T; Ayyagari S; Callahan TD; Civello KC; Thal SG; Wilkoff BL; Chung MK
    Am J Cardiol; 2008 Feb; 101(3):359-63. PubMed ID: 18237600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of right ventricular peak systolic pressure to major adverse events in patients undergoing cardiac resynchronization therapy.
    Tedrow UB; Kramer DB; Stevenson LW; Stevenson WG; Baughman KL; Epstein LM; Lewis EF
    Am J Cardiol; 2006 Jun; 97(12):1737-40. PubMed ID: 16765124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.